As of June 30, the company had cash and cash equivalents of approximately $33.4M.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio Completes Phase I/II Trial for INKmune™
- INmune Bio options imply 16.2% move in share price post-earnings
- Largest borrow rate increases among liquid names
- INmune Bio reports Phase I/II trial of INKmune met primary, secondary endpoints
- INmune Bio options imply 14.9% move in share price post-earnings